Director Nicholas Augustinos filed a Form 4 with the SEC on September 16, 2026, reporting the sale of DexCom Inc. common stock on September 14 and 15, 2026, pursuant to a pre-established 10b5-1 trading plan.

Key Highlights

  • First sale: 1,550 shares of common stock were disposed of on September 14, 2026, at $84.02 per share.
  • Second sale: 6,539 shares were disposed of on September 15, 2026, at $84.04 per share.
  • Post-transaction ownership: Following the September 15 sale, the reporting person held 29,293 shares indirectly through the Kirschner/Augustinos Revocable Trust.
  • 10b5-1 Plan: The plan was adopted by Mr. Augustinos on June 10, 2026, to allow orderly disposition of shares.
  • Unvested RSUs: The filing also reports 5,575 unvested restricted stock units granted on May 28, 2026, vesting on the earlier of the one-year anniversary of the grant date or the date of DexCom's 2027 Annual Meeting of Stockholders.
  • Ownership structure: All reported common stock is held indirectly by the Kirschner/Augustinos Revocable Trust, of which the reporting person is a trustee.

Nicholas Augustinos Reports Two-Day Share Disposition at DexCom Inc.

According to the filing, Nicholas Augustinos, a director of DexCom Inc. (NASDAQ:DXCM), sold a combined 8,089 shares of common stock across two transactions on September 14 and 15, 2026. The September 14 transaction involved the disposal of 1,550 shares at $84.02 per share, reducing indirect beneficial ownership to 35,832 shares. The following day, an additional 6,539 shares were sold at $84.04 per share, leaving 29,293 shares held indirectly through the Kirschner/Augustinos Revocable Trust.

The filing states that both sales were made pursuant to a Rule 10b5-1 plan that Mr. Augustinos adopted on June 10, 2026. According to the filing, "This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Augustinos." The Form 4 indicates the box confirming a Rule 10b5-1(c) transaction was checked for both sales. All shares sold were held indirectly through the Kirschner/Augustinos Revocable Trust, with Mr. Augustinos serving as trustee.

Separately, the filing discloses 5,575 unvested restricted stock units, which the filing describes as granted on May 28, 2026, and set to vest "on the earlier of the one year anniversary of the grant date or the date of DexCom, Inc.'s 2027 Annual Meeting of Stockholders." These RSUs appear in Table I and are reported as directly held. The Form 4 was signed on September 16, 2026, by Jereme M. Sylvain as Attorney-in-Fact for Nicholas Augustinos.

What Was Disclosed

Director Nicholas Augustinos reported two sales of DexCom common stock on September 14 and 15, 2026, totaling 8,089 shares at prices of $84.02 and $84.04 per share respectively, both executed under a 10b5-1 plan adopted June 10, 2026, with shares held through a revocable trust.